PharmaX Solutions sold to BioPhorum (Five Arrows)

ONLINE PLATFORM SPECIALIZED IN NUTRITIONAL SUPPLEMENTS SOLD TO LABORATORIOS RUBIÓ, A PHARMACEUTICAL GROUP

offmann & Partner is pleased to announce that it has advised the shareholders of Nostos Genomics GmbH (“Nostos”) as M&A advisors in the successful acquisition by Limbus Medical Technologies GmbH (“Limbus”). Two leaders in genomic software are coming together – combining Limbus’ clinical-grade workflows with Nostos’ cutting-edge AI technology for variant interpretation.

Sale of Allderma to Avia Pharma

Senn Chemicals AG (“Senn Chemicals”) announces the closing of the acquisition by Granules Peptides Private Limited, a wholly owned subsidiary of Granules India Limited (“Granules”) today April 10th, 2025. The acquisition enables Senn Chemicals to support its future as a leading peptide manufacturing company. Already back in February 2025, the Senn Family signed a share purchase agreement to transfer 100% of the shares of Senn Chemicals to Granules. Since its founding over 60 years ago by Guido Senn, Senn Chemicals has been a private, family-owned Swiss CDMO specialising in peptides. After a careful evaluation of potential ownership transfer options, the family decided to sell the company to Granules, a vertically integrated pharmaceutical company, focused on manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). The Senn Chemicals brand and its site in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus. The acquisition brings Senn Chemical’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments together with Granules’ market presence in India and the USA. Together with Senn Chemical’s expertise Granules gains the capabilities into high-growth peptide-based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn Chemicals have active in the development of GLP-1 based APIs, and more peptide-based APIs are planned to be developed using Senn Chemical’s R&D capabilities. The acquisition marks Granules’ foray into CDMO segments, leveraging Senn Chemical’s existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn Chemical’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn Chemical’s presence in Europe provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint. Hoffmann & Partner (www.hoffmann-partner.com), the Basel-based M&A advisory firm specialising in life sciences, has acted as the exclusive M&A financial advisor in the transaction and advised the shareholders of Senn Chemicals with technical and industrial expertise.

Advisers to specialist manufacturer of fibre optic connectivity products, Fibreactive, on its sale to discoverIE Group plc.

Advisers to the shareholders of Elite Vehicle Supplies on its investment from Vehicle Accessories Solutions Ltd T/A Motormax.